← Go back

Title of the publicationSusceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997–2003)
Abstract

A total of 30,634 global Enterobacteriaceae isolates collected from the MYSTIC (Meropenem Yearly Surveillance Test Information
Collection) Programme were tested using a reference methodology against meropenem and seven other broad-spectrum agents commonly
used in the hospital setting (1997–2003). The most active compound was meropenem (99.6% susceptible), followed by imipenem (98.4%),
cefepime (94.0%), gentamicin (86.8%), piperacillin/tazobactam (85.8%), ceftazidime (85.0%), ciprofloxacin (84.6%), and tobramycin
(84.5%).

Name of the first authorTurner, Phillip J.
Year of publication2004
Study design of the publicationCross sectional study
Method for data collection and analysis
  • Quantitative data - Quantitative data were used during the intervention
Quantitative data - Quantitative data were used during the intervention
Sector
  • Human - All activities regarding organisations and individuals involved in health products and services
Sub-sectorSub-sectors are further units of demarcation within a sector E.g. awareness campaign from veterinarians to cat owners about toxoplasmosis drug resistance and transmission of resistant bacteria: ANIMAL, PETS
Subsector (human)
  • Healthcare delivery
Healthcare delivery